Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Update

Structure Therapeutics Inc. (NASDAQ:GPCR) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 4,110,000 shares, a growth of 9.9% from the March 31st total of 3,740,000 shares. Based on an average daily volume of 553,100 shares, the short-interest ratio is currently 7.4 days. Approximately 9.9% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a research note on Thursday, April 18th. Lifesci Capital reissued an “outperform” rating on shares of Structure Therapeutics in a research note on Tuesday, February 27th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $85.71.

Structure Therapeutics Trading Up 0.2 %

Shares of GPCR stock traded up $0.06 during mid-day trading on Wednesday, reaching $39.50. The stock had a trading volume of 71,269 shares, compared to its average volume of 563,764. The stock’s 50-day moving average price is $39.44 and its two-hundred day moving average price is $47.25. Structure Therapeutics has a 52-week low of $21.79 and a 52-week high of $75.02. The firm has a market capitalization of $1.84 billion and a PE ratio of -47.52.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Friday, March 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.04. On average, equities research analysts forecast that Structure Therapeutics will post -0.98 earnings per share for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Federated Hermes Inc. increased its position in shares of Structure Therapeutics by 104.2% during the fourth quarter. Federated Hermes Inc. now owns 2,267,206 shares of the company’s stock valued at $92,411,000 after buying an additional 1,157,006 shares during the period. Adage Capital Partners GP L.L.C. increased its position in shares of Structure Therapeutics by 835.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 1,799,923 shares of the company’s stock valued at $90,752,000 after buying an additional 1,607,525 shares during the period. Wellington Management Group LLP increased its position in shares of Structure Therapeutics by 312.6% during the third quarter. Wellington Management Group LLP now owns 867,579 shares of the company’s stock valued at $43,743,000 after buying an additional 657,310 shares during the period. FMR LLC increased its position in shares of Structure Therapeutics by 28.5% during the third quarter. FMR LLC now owns 1,590,335 shares of the company’s stock valued at $80,185,000 after buying an additional 352,600 shares during the period. Finally, Allspring Global Investments Holdings LLC purchased a new position in shares of Structure Therapeutics during the fourth quarter valued at about $1,960,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.